Epoch Biosciences, Inc. (EBIO) Expands License Agreement With Celera DiagnosticsBiopure Corporation (BPUR) Appoints New President And Chief Executive Officer And Restructures The Company; Cuts Jobs
Epoch Biosciences, Inc. (EBIO) Enters Collaboration With ARUP Laboratories For MGB Eclipse(TM) Detection ReagentsTumor Starving Protein Identified
William G. The combination Florida Marlins Hat of our MGB and Eclipse Dark Quencher makes it possible to design shorter DNA probes that can accurately detect SNPs and that demonstrate very low background, improving assay performance. These advantages have been recognized by our commercial partners, including ABI, Celera Diagnostics, and QIAGEN, and are appreciated by our customers, including Millennium Pharmaceuticals and the National Cancer Institute."MGB technology is based on a potent class of naturally occurring antibiotics that bind to the minor groove of double stranded DNA. When attached to either the 5' or 3' terminus of DNA probes, hydrophobic binding of MGB molecules to the minor groove stabilizes DNA duplexes formed by these probes hybridizing to their complementary targets. This allows the use of shorter probes with higher sensitivity to mismatches, which is particularly beneficial in the design of probes for the analysis of single nucleotide polymorphisms (SNP) or short, New York Yankees Caps
Epoch Biosciences, Inc.
Safe Harbor Statement
Epoch Biosciences, Inc. (EBIO) To Host Conference Call And Release First Quarter Results On May 4"Fidelity Gene" Found; Scientists Turn Promiscuous Male Nike Hats With Strap
BOTHELL, Wash., June 23 /PRNewswire FirstCall/ Epoch Biosciences, Inc. Patent number 6,727,356 on "Fluorescent Quenching Detection Reagents and Methods."
1 Expands Minor Groove Binder And Eclipse Dark Quencher Patent Portfolio
Mice Into Monogamous Mates
that third parties assert proprietary rights that preclude Epoch or its distributors from marketing Epoch's products and technologies. These factors and others may cause actual results to differ materially from the anticipated results. Additional information about potential risk factors that could affect Epoch's business and financial results is included in Epoch's Annual Report on Form 10 K for the year ended December 31, 2003 and in other reports filed from time to time with the Securities and Exchange Commission. These forward looking statements speak only as to the date of this release and Epoch undertakes no obligation to update or revise the forward looking statements, whether as a result of new information, future events, or otherwise.
The Eclipse Dark Quencher is a pioneering technology developed by Epoch Biosciences that when attached with a fluorescent dye to a DNA probe, suppresses the signal generated by the dye until the probe binds to its target DNA. It offers higher sensitivity in real time PCR probes due to lower background fluorescence, is applicable in a broad range of detection systems, quenches a broader dye emission spectra range, and is compatible with simple and robust DNA synthesis procedures.
This patent strengthens Epoch's position as the leader in minor groove binder technology and the use and development of fluorescent quenchers. This patent covers the use of MGB(TM) and Eclipse(R) Dark Quencher technology in designing probes that work in the narrow temperature range used in genetic analysis systems. This development greatly improves the performance of hybridization based systems for genetic analysis, including detection of single nucleotide polymorphisms (SNPs) on today's sophisticated high throughput platforms, and allows the generation of highly quantitative gene expression systems. in the research field, and MGB and Eclipse Dark Quencher technology comprise a key element of Applied Biosystems' TaqMan(R) MGB products and BioControl System's food testing products.
About Epoch Biosciences
Eclipse Dark Quencher
Epoch Biosciences, Inc. (EBIO) Announces First Quarter Financial ResultsGene Patterns Remain Skewed After Quitting Smoking
Except for the historical information contained herein, the matters set forth in this press release are forward looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward looking statements are subject to risks and uncertainties, including but not limited to the possibility that the products utilizing Epoch Biosciences' technologies may not be commercially successful or Nike Cap Red
MGB and Eclipse are trademarks of Epoch Biosciences, Inc. TaqMan is a registered trademark of Roche Molecular Systems, Inc., licensed to Applera Corporation.
Epoch Biosciences, Inc. develops and sells proprietary products with commercial applications in the genomics and molecular diagnostics fields. Epoch's technology has numerous applications including the detection of inherited diseases, single nucleotide polymorphisms (SNPs) to identify individuals at risk for disease or adverse drug reactions, and gene expression measurement. The Company's chemical reagents enhance the performance of genetic analysis procedures, and are compatible with the majority of DNA analysis systems currently employed or under development for research and diagnostic uses. The Company has an established presence in the research market through licenses to leading genomics companies, global distribution agreements and direct sales to end users. Epoch also participates in the industrial/bioterrorism sectors and is currently entering the diagnostics market.
conserved sequences of viral genomes or multi gene families for which limited target sequence is available. Epoch Biosciences was the first to recognize and utilize the enhanced performance and expanded assay design flexibility that MGB technology provides for DNA probe based detection systems.
Colorado Rockies Hats
Detroit Tigers Caps
Belt Ferragamo Price
New Era Cap Atlanta
New Era Ny Snapback
Gucci Belt Snake Gg
New York Yankees Hat
Mens Lv Belts
Chicago Cubs Hat 47
New Era Los Angeles Kings
Gucci Belt Authentic
Nike Cap Girls
Cleveland Indians Hats New Era
Lv Belt Damier